Cite
MLA Citation
N. Harbeck et al.. “1815 A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes.” European journal of cancer, vol. 51, n.d., pp. S270–S271. http://access.bl.uk/ark:/81055/vdc_100030628126.0x000014